医药导报
醫藥導報
의약도보
HERALD OF MEDICINE
2014年
8期
1012-1017
,共6页
抗风湿药物%关节炎,风湿性%血脂%心血管事件
抗風濕藥物%關節炎,風濕性%血脂%心血管事件
항풍습약물%관절염,풍습성%혈지%심혈관사건
Antirheumatic drug%Arthritis,rheumatoid%Blood lipid%Cardiovascular events
目的探讨抗风湿药物( DMARDs)治疗类风湿关节炎( RA)患者早发性动脉硬化的效果和机制,为减少RA患者心血管意外的发生提供理论依据。方法对72例早期RA患者,分别在治疗前后检测红细胞沉降速率( ESR)和超敏C-反应蛋白(hs-CRP)以评价患者炎症情况,并监测颈动脉内-中膜厚度(cIMT)以及内皮依赖性血管舒张功能(ED-FMD)。在研究过程中使用疾病程度指数评级标准(DAS28)评估RA疾病严重程度,使用健康评估问卷-伤残指数( HAQ-DI)评级标准评定患者的生活质量。根据患者疾病严重程度应用甲氨蝶呤( MTX)、羟氯喹( HCQ)和柳氮磺吡啶(SSZ)3种药物单独或者联合治疗。结果治疗1年后,ESR、hs-CRP、DAS28与HAQ-DI均有显著改善(均P<0.01),同时患者的血脂状况也有明显变化。体质量指数(BMI)的差异无统计学意义(P=0.58)。治疗1年后cIMT值(0.43依0.08) mm比基础水平(0.50依0.16) mm显著下降(P=0.002)。 FMD%由基础水平5.26升高至7.57,差异有统计学意义(P=0.041)。结论使用DMARDs对RA进行早期干预不仅能有效控制病情,而且可以延缓动脉粥样硬化的进程,还可以降低心血管事件引起的病死率。
目的探討抗風濕藥物( DMARDs)治療類風濕關節炎( RA)患者早髮性動脈硬化的效果和機製,為減少RA患者心血管意外的髮生提供理論依據。方法對72例早期RA患者,分彆在治療前後檢測紅細胞沉降速率( ESR)和超敏C-反應蛋白(hs-CRP)以評價患者炎癥情況,併鑑測頸動脈內-中膜厚度(cIMT)以及內皮依賴性血管舒張功能(ED-FMD)。在研究過程中使用疾病程度指數評級標準(DAS28)評估RA疾病嚴重程度,使用健康評估問捲-傷殘指數( HAQ-DI)評級標準評定患者的生活質量。根據患者疾病嚴重程度應用甲氨蝶呤( MTX)、羥氯喹( HCQ)和柳氮磺吡啶(SSZ)3種藥物單獨或者聯閤治療。結果治療1年後,ESR、hs-CRP、DAS28與HAQ-DI均有顯著改善(均P<0.01),同時患者的血脂狀況也有明顯變化。體質量指數(BMI)的差異無統計學意義(P=0.58)。治療1年後cIMT值(0.43依0.08) mm比基礎水平(0.50依0.16) mm顯著下降(P=0.002)。 FMD%由基礎水平5.26升高至7.57,差異有統計學意義(P=0.041)。結論使用DMARDs對RA進行早期榦預不僅能有效控製病情,而且可以延緩動脈粥樣硬化的進程,還可以降低心血管事件引起的病死率。
목적탐토항풍습약물( DMARDs)치료류풍습관절염( RA)환자조발성동맥경화적효과화궤제,위감소RA환자심혈관의외적발생제공이론의거。방법대72례조기RA환자,분별재치료전후검측홍세포침강속솔( ESR)화초민C-반응단백(hs-CRP)이평개환자염증정황,병감측경동맥내-중막후도(cIMT)이급내피의뢰성혈관서장공능(ED-FMD)。재연구과정중사용질병정도지수평급표준(DAS28)평고RA질병엄중정도,사용건강평고문권-상잔지수( HAQ-DI)평급표준평정환자적생활질량。근거환자질병엄중정도응용갑안접령( MTX)、간록규( HCQ)화류담광필정(SSZ)3충약물단독혹자연합치료。결과치료1년후,ESR、hs-CRP、DAS28여HAQ-DI균유현저개선(균P<0.01),동시환자적혈지상황야유명현변화。체질량지수(BMI)적차이무통계학의의(P=0.58)。치료1년후cIMT치(0.43의0.08) mm비기출수평(0.50의0.16) mm현저하강(P=0.002)。 FMD%유기출수평5.26승고지7.57,차이유통계학의의(P=0.041)。결론사용DMARDs대RA진행조기간예불부능유효공제병정,이차가이연완동맥죽양경화적진정,환가이강저심혈관사건인기적병사솔。
Objective To investigate the effect of DMARDs on the prevention of early-onset atherosclerosis in rheumatoid arthritis ( RA) patients for exploring an appropriate schedule to reduce cardiovascular events. Methods Seventy-two patients with early RA were included in this study. Erythrocyte sedimentation rate ( ESR) and high sensitivity C reactive protein ( hs-CRP) were detected before and after treatment to evaluate inflammation. Carotid intima-media thickness ( cIMT) and endothelium-dependent flow-mediated vasodilatation (ED-FMD) were monitored. Disease Activity Score in 28 Joints (DAS28) and health assessment questionnaire-disability index ( HAQ-DI) was used to assess severity degree of RA and life quality of the patients, respectively. The patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ) and sulfasalazine (SSZ) alone or combined based on severity of RA. Results After 1 year of treatment, ESR, hs-CRP, DAS28 and HAQ-DI were significantly improved (all P<0. 01). At the same time, the serum lipid levels also had obvious changes. However, there was no obvious difference in body mass index ( BMI) after 1 year. The cIMT ratio value was significantly decreased compared to baseline (0. 43±0. 08 mm vs. 0. 50±0. 16 mm, P=0. 002), and FMD% also significantly improved from basic value of 5. 26 to 7. 57 after treatment (P=0. 041). Conclusion Early intervention of RA by using DMARDs can effectively control the disease and slow the progression of atherosclerosis, but also reduce cardiovascular mortality.